ContributorsPublishersAdvertisers

Nivolumab Misses Mark in Japanese Patients With Platinum-Resistant Ovarian Cancer

onclive.com
 2022-01-18

Nivolumab did not significantly improve overall survival compared with chemotherapy in Japanese patients with platinum-resistant ovarian cancer. Nivolumab (Opdivo) did not significantly improve overall survival (OS) compared with chemotherapy in Japanese patients with platinum-resistant ovarian cancer, missing the primary end point of the phase 3 NINJA trial (JapicCTI-153004).1. Results,...

www.onclive.com

Comments / 0

Comments / 0